CIA
BIO icon

Cape Investment Advisory’s Bio-Rad Laboratories Class A BIO Stock Holding History

Cape Investment Advisory’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$54.6K Buy
+186
New +$52.8K 0.01% 477
2026
Q1 		– Sell
-156
Closed -$47.3K – 321
2025
Q4 		$47.3K Sell
156
-5
-3% -$1.56K 0.01% 427
2025
Q3 		$45.1K Buy
161
+18
+13% +$4.9K 0.04% 235
2025
Q2 		$34.5K Buy
143
+3
+2% +$709 0.01% 419
2025
Q1 		$34.1K Buy
140
+23
+20% +$6.92K 0.01% 395
2024
Q4 		$38.4K Buy
+117
New +$39.7K 0.02% 365

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Cape Investment Advisory's BIO Position: Q2 2026 in Review

Cape Investment Advisory opened a new position in Bio-Rad Laboratories Class A (BIO) in Q2 2026: 186 shares worth $54.6K. The stake represents 0.01% of the portfolio and ranks #477 among its holdings. This is a return to the name: Cape Investment Advisory previously reported a position in BIO as recently as Q4 2025.

Cape Investment Advisory first reported a position in BIO in Q4 2024 and has held it in 6 quarters since. 400 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Cape Investment Advisory held 186 shares of Bio-Rad Laboratories Class A worth $54.6K as of Q2 2026.
  • Bio-Rad Laboratories Class A was a new Cape Investment Advisory position in Q2 2026.
  • Bio-Rad Laboratories Class A made up 0.01% of Cape Investment Advisory's portfolio in Q2 2026, its #477 holding.
  • Cape Investment Advisory first reported a position in Bio-Rad Laboratories Class A in Q4 2024 and has held it in 6 quarters since.
  • 400 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Cape Investment Advisory's 13F filing for Q2 2026, filed 23 Jul 2026.